Drugs / CD-GA-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07050394 | Jun 2025 → Jun 2028 expected | colorectal cancer | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD-GA-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07050394 ↗ |
| Route | Intravenous | “CD-GA-102 will be administered intravenously at 50 μg per dose” NCT07050394 ↗ |